Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 6
2006 2
2007 1
2008 3
2009 3
2010 1
2011 4
2012 9
2013 7
2014 9
2015 5
2016 8
2017 7
2018 6
2019 5
2020 7
2021 6
2022 7
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: van leth f. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Review.
Testing for LTBI: more of the same or a step forward?
van Leth F, Sester M. van Leth F, et al. Int J Tuberc Lung Dis. 2018 Jun 1;22(6):591. doi: 10.5588/ijtld.18.0267. Int J Tuberc Lung Dis. 2018. PMID: 29862938 No abstract available.
Availability and costs of medicines for the treatment of tuberculosis in Europe.
Günther G, Guglielmetti L, Leu C, Lange C, van Leth F; Tuberculosis Network European Trials group. Günther G, et al. Among authors: van leth f. Clin Microbiol Infect. 2023 Jan;29(1):77-84. doi: 10.1016/j.cmi.2022.07.026. Epub 2022 Aug 10. Clin Microbiol Infect. 2023. PMID: 35961488 Free PMC article.
Estimating the contribution of subclinical tuberculosis disease to transmission: An individual patient data analysis from prevalence surveys.
Emery JC, Dodd PJ, Banu S, Frascella B, Garden FL, Horton KC, Hossain S, Law I, van Leth F, Marks GB, Nguyen HB, Nguyen HV, Onozaki I, Quelapio MID, Richards AS, Shaikh N, Tiemersma EW, White RG, Zaman K, Cobelens F, Houben RMGJ. Emery JC, et al. Among authors: van leth f. Elife. 2023 Dec 18;12:e82469. doi: 10.7554/eLife.82469. Elife. 2023. PMID: 38109277 Free PMC article. Review.
Relapse-free cure from multidrug-resistant tuberculosis in Germany.
Heyckendorf J, van Leth F, Kalsdorf B, Olaru ID, Günther G, Salzer HJF, Terhalle E, Rolling T, Glattki G, Müller M, Schuhmann M, Avsar K, Lange C. Heyckendorf J, et al. Among authors: van leth f. Eur Respir J. 2018 Feb 21;51(2):1702122. doi: 10.1183/13993003.02122-2017. Print 2018 Feb. Eur Respir J. 2018. PMID: 29467205 Free article. No abstract available.
103 results